619 related articles for article (PubMed ID: 17063130)
1. The lifetime cost of current human immunodeficiency virus care in the United States.
Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
Hornberger J; Kilby JM; Wintfeld N; Green J
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):240-7. PubMed ID: 16545010
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.
Sax PE; Losina E; Weinstein MC; Paltiel AD; Goldie SJ; Muccio TM; Kimmel AD; Zhang H; Freedberg KA; Walensky RP
J Acquir Immune Defic Syndr; 2005 May; 39(1):69-77. PubMed ID: 15851916
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy.
Hornberger J; Green J; Wintfeld N; Cavassini M; Rockstroh J; Giuliani G; De Carli C; Lazzarin A
HIV Clin Trials; 2005; 6(2):92-102. PubMed ID: 15983893
[TBL] [Abstract][Full Text] [Related]
6. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults.
Sloan CE; Champenois K; Choisy P; Losina E; Walensky RP; Schackman BR; Ajana F; Melliez H; Paltiel AD; Freedberg KA; Yazdanpanah Y;
AIDS; 2012 Jan; 26(1):45-56. PubMed ID: 22008655
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
10. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
Krentz HB; Gill MJ
HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
[TBL] [Abstract][Full Text] [Related]
11. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
12. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
13. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
14. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
15. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina.
Rampaul M; Edun B; Gaskin M; Albrecht H; Weissman S
South Med J; 2018 Jun; 111(6):355-358. PubMed ID: 29863227
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials for enfuvirtide (Fuzeon, T-20).
Crabb C
AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
[No Abstract] [Full Text] [Related]
[Next] [New Search]
